Literature DB >> 30120408

Altered ErbB4 splicing and cortical parvalbumin interneuron dysfunction in schizophrenia and mood disorders.

Daniel W Chung1, Youjin Chung1,2, H Holly Bazmi1, David A Lewis3.   

Abstract

Working memory requires the activity of parvalbumin (PV) interneurons in the dorsolateral prefrontal cortex (DLPFC). Impaired working memory and lower PV expression in the DLPFC are reported in schizophrenia and to a lesser degree in mood disorders. We previously proposed that activity-dependent PV expression is lower in schizophrenia due to a shift in the splicing of erb-b2 receptor tyrosine kinase 4 (ErbB4) transcripts from major to inactive minor variants that reduces excitatory drive to PV interneurons. Here, we tested the hypothesis that the degree of major-to-minor shift in ErbB4 splicing predicts the level of PV expression across schizophrenia and mood disorders. Levels of ErbB4 splice variants and PV mRNA were quantified by PCR in the DLPFC from 40 matched tetrads (N = 160 subjects) of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), and unaffected comparison subjects. Relative to unaffected comparison subjects, the magnitude of increases in minor variant levels and decreases in major variant levels was greatest in schizophrenia, intermediate in BD, and least in MDD. The same rank order was present for the magnitude of increases in the composite splicing score, which reflects the degree of major-to-minor shift across all ErbB4 splice loci, and for the magnitude of deficient PV expression. Finally, the composite splicing score negatively predicted PV expression across all subject groups. Together, these findings demonstrate a shared relationship between ErbB4 splicing and PV expression and suggest that scaling of the major-to-minor shift in ErbB4 splicing may influence the severity of deficient PV interneuron activity across diagnoses.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30120408      PMCID: PMC6180093          DOI: 10.1038/s41386-018-0169-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  46 in total

Review 1.  Function of ERBB4 is determined by alternative splicing.

Authors:  Ville Veikkolainen; Katri Vaparanta; Kalle Halkilahti; Kristiina Iljin; Maria Sundvall; Klaus Elenius
Journal:  Cell Cycle       Date:  2011-08-15       Impact factor: 4.534

2.  Elevated ErbB4 mRNA is related to interneuron deficit in prefrontal cortex in schizophrenia.

Authors:  Dipesh Joshi; Janice M Fullerton; Cynthia Shannon Weickert
Journal:  J Psychiatr Res       Date:  2014-03-03       Impact factor: 4.791

3.  Reduced Labeling of Parvalbumin Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia.

Authors:  John F Enwright; Sowmya Sanapala; Aaron Foglio; Raissa Berry; Kenneth N Fish; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2016-02-12       Impact factor: 7.853

4.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

5.  Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia.

Authors:  Daniel W Chung; Kenneth N Fish; David A Lewis
Journal:  Am J Psychiatry       Date:  2016-07-22       Impact factor: 18.112

6.  Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery.

Authors:  T E Goldberg; J M Gold; R Greenberg; S Griffin; S C Schulz; D Pickar; J E Kleinman; D R Weinberger
Journal:  Am J Psychiatry       Date:  1993-09       Impact factor: 18.112

7.  Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders.

Authors:  Abraham Reichenberg; Philip D Harvey; Christopher R Bowie; Ramin Mojtabai; Jonathan Rabinowitz; Robert K Heaton; Evelyn Bromet
Journal:  Schizophr Bull       Date:  2008-05-20       Impact factor: 9.306

8.  Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder.

Authors:  Anabel Martínez-Arán; Eduard Vieta; María Reinares; Francesc Colom; Carla Torrent; Jose Sánchez-Moreno; Antonio Benabarre; José Manuel Goikolea; Mercè Comes; Manel Salamero
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia.

Authors:  Nikolaos Mellios; Hsien-Sung Huang; Stephen P Baker; Marzena Galdzicka; Edward Ginns; Schahram Akbarian
Journal:  Biol Psychiatry       Date:  2009-01-01       Impact factor: 13.382

View more
  14 in total

Review 1.  Parvalbumin interneuron alterations in stress-related mood disorders: A systematic review.

Authors:  George Perlman; Arnaud Tanti; Naguib Mechawar
Journal:  Neurobiol Stress       Date:  2021-08-12

Review 2.  Cognitive Dysfunction and Prefrontal Cortical Circuit Alterations in Schizophrenia: Developmental Trajectories.

Authors:  Samuel J Dienel; Kirsten E Schoonover; David A Lewis
Journal:  Biol Psychiatry       Date:  2022-03-10       Impact factor: 12.810

3.  Searching for the "final proof" of schizophrenia.

Authors:  David A Lewis; Samuel J Dienel; Daniel W Chung
Journal:  Schizophr Res       Date:  2021-11-26       Impact factor: 4.662

4.  Developmental, neurochemical, and behavioral analyses of ErbB4 Cyt-1 knockout mice.

Authors:  Larissa Erben; Jacqueline P Welday; Marie E Cronin; Ricardo Murphy; Miguel Skirzewski; Detlef Vullhorst; Steven L Carroll; Andres Buonanno
Journal:  J Neurochem       Date:  2022-05-06       Impact factor: 5.546

5.  Temporal Dynamics of the Neuregulin-ErbB Network in the Murine Prefrontal Cortex across the Lifespan.

Authors:  Clare Paterson; Brooke Cumming; Amanda J Law
Journal:  Cereb Cortex       Date:  2020-05-14       Impact factor: 5.357

Review 6.  Genetic and Epigenetic Alterations Underlie Oligodendroglia Susceptibility and White Matter Etiology in Psychiatric Disorders.

Authors:  Xianjun Chen; Huifeng Duan; Lan Xiao; Jingli Gan
Journal:  Front Genet       Date:  2018-11-22       Impact factor: 4.599

Review 7.  Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.

Authors:  Jason Smucny; Samuel J Dienel; David A Lewis; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2021-07-20       Impact factor: 7.853

Review 8.  An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data.

Authors:  Chu-Yi Zhang; Xiao Xiao; Zhuohua Zhang; Zhonghua Hu; Ming Li
Journal:  Mol Psychiatry       Date:  2021-03-08       Impact factor: 15.992

9.  Sex-Specific Role for the Long Non-coding RNA LINC00473 in Depression.

Authors:  Orna Issler; Yentl Y van der Zee; Aarthi Ramakrishnan; Junshi Wang; Chunfeng Tan; Yong-Hwee E Loh; Immanuel Purushothaman; Deena M Walker; Zachary S Lorsch; Peter J Hamilton; Catherine J Peña; Erin Flaherty; Brigham J Hartley; Angélica Torres-Berrío; Eric M Parise; Hope Kronman; Julia E Duffy; Molly S Estill; Erin S Calipari; Benoit Labonté; Rachael L Neve; Carol A Tamminga; Kristen J Brennand; Yan Dong; Li Shen; Eric J Nestler
Journal:  Neuron       Date:  2020-04-17       Impact factor: 17.173

Review 10.  Transcriptomic Insight Into the Polygenic Mechanisms Underlying Psychiatric Disorders.

Authors:  Leanna M Hernandez; Minsoo Kim; Gil D Hoftman; Jillian R Haney; Luis de la Torre-Ubieta; Bogdan Pasaniuc; Michael J Gandal
Journal:  Biol Psychiatry       Date:  2020-06-12       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.